journal article·2023-05-10

Layer-by-Layer Microneedle-Mediated rhEGF Transdermal Delivery for Enhanced Wound Epidermal Regeneration and Angiogenesis

Renqiang Yuan, Ning Yang, Yueru Huang, Weikun Li, Yi Zeng, Zonghao Liu, Xin Tan, Fang Feng, Qianli Zhang, Shao Su, Cuilin Chu, Ling Liu, Liqin Ge

ACS Applied Materials & Interfaces· Volume 15· Issue 18
Publisher page

Abstract

Appropriate treatments for acute traumas tend to avoid hemorrhages, vascular damage, and infections. However, in the homeostasis-imbalanced wound microenvironment, currently developed therapies could not precisely and controllably deliver biomacromolecular drugs, which are confronted with challenges due to large molecular weight, poor biomembrane permeability, low dosage, rapid degradation, and bioactivity loss. To conquer this, we construct a simple and effective layer-by-layer (LBL) self-assembly transdermal delivery patch, bearing microneedles (MN) coated with recombinant human epidermal growth factor (LBL MN-rhEGF) for a sustained release to wound bed driven by typical electrostatic force. Pyramidal LBL MN-rhEGF patches hold so enough mechanical strength to penetrate the stratum corneum, and generated microchannels allow rhEGF direct delivery in situ. The administrable delivery of biomacromolecular rhEGF through hierarchically coated MN arrays follows the diffusion mechanism of Fick’s second law. Numerous efforts further have illustrated that finger-pressing LBL MN-rhEGF patches could not only promote cell proliferation of normal human dermal fibroblasts (NHDF) and human umbilical vein endothelial cells (HUVEC) in vitro but also take significant effects (regenerative epidermis: ∼144 μm; pro-angiogenesis: higher CD31 expression) in accelerating wound healing of mechanically injured rats, compared to the traditional dressing, which relies on passive diffusion. Our proof-of-concept features novel LBL biomacromolecular drug-delivery systems and self-administrated precision medicine modes at the point of care.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advancements in Transdermal Drug Delivery · Tendon Structure and Treatment · Wound Healing and Treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

State Key Laboratory of Organic Electronics and Information Displays & Jiangsu Key Laboratory for Biosensors, Institute of Advanced Materials (IAM), Nanjing University of Posts and Telecommunications, Nanjing 210023, P.R. China

State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing 210096, P.R. China

Jiangsu Provincial Key Laboratory of Critical Care Medicine, Department of Critical Care Medicine, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, P.R. China

Jiangsu Yuyue Medical Equipment & Supply Co., Ltd., Development Zone, Danyang 212310, P.R. China

School of Chemistry and Life Science, Suzhou University of Science and Technology, Suzhou 215009, P.R. China

Funding

Government of Jiangsu Province · Nanjing University of Posts and Telecommunications · Jiangsu Science and Technology Department

References (49)

Show source-provided references
1. 10.1016/j.biotechadv.2021.10778110.1016/j.biotechadv.2021.107781 ↗
2. 10.1089/wound.2020.123210.1089/wound.2020.1232 ↗
3. 10.1002/adfm.20220187510.1002/adfm.202201875 ↗
4. 10.1002/adhm.20170046510.1002/adhm.201700465 ↗
5. 10.17219/acem/9230410.17219/acem/92304 ↗
6. 10.1089/wound.2020.121810.1089/wound.2020.1218 ↗
7. 10.1039/D1BM01062J10.1039/D1BM01062J ↗
8. 10.1117/1.JBO.21.9.09130410.1117/1.JBO.21.9.091304 ↗
9. 10.1007/s40820-022-00928-z10.1007/s40820-022-00928-z ↗
10. 10.1021/acsami.0c1300910.1021/acsami.0c13009 ↗
11. 10.1016/j.actbio.2021.05.02710.1016/j.actbio.2021.05.027 ↗
12. 10.1021/acsami.2c1956610.1021/acsami.2c19566 ↗
13. 10.1016/j.biopha.2018.10.07810.1016/j.biopha.2018.10.078 ↗
14. 10.1021/acsnano.6b0610410.1021/acsnano.6b06104 ↗
15. 10.1007/s40820-021-00611-910.1007/s40820-021-00611-9 ↗
16. 10.1016/j.bioactmat.2020.02.00410.1016/j.bioactmat.2020.02.004 ↗
17. 10.1039/D2BM00281G10.1039/D2BM00281G ↗
18. 10.1038/s41467-022-34716-510.1038/s41467-022-34716-5 ↗
19. 10.3390/pharmaceutics1502035510.3390/pharmaceutics15020355 ↗
20. 10.1080/10717544.2018.155925810.1080/10717544.2018.1559258 ↗
21. 10.1126/science.277.5330.123210.1126/science.277.5330.1232 ↗
22. 10.1016/j.cej.2021.12918210.1016/j.cej.2021.129182 ↗
23. 10.1039/C7CS00406K10.1039/C7CS00406K ↗
24. 10.1016/j.actbio.2021.08.04210.1016/j.actbio.2021.08.042 ↗
25. 10.1016/j.eurpolymj.2022.11116410.1016/j.eurpolymj.2022.111164 ↗
26. 10.1016/j.jcis.2022.11.15110.1016/j.jcis.2022.11.151 ↗
27. 10.1016/j.msec.2020.11124410.1016/j.msec.2020.111244 ↗
28. 10.1016/j.apsusc.2018.12.27810.1016/j.apsusc.2018.12.278 ↗
29. 10.1016/j.cej.2021.13421210.1016/j.cej.2021.134212 ↗
30. 10.1002/adhm.20220229610.1002/adhm.202202296 ↗
31. 10.1016/j.ijbiomac.2019.09.01310.1016/j.ijbiomac.2019.09.013 ↗
32. 10.1007/s00289-016-1898-610.1007/s00289-016-1898-6 ↗
33. 10.1038/s41467-022-31740-310.1038/s41467-022-31740-3 ↗
34. 10.1002/adfm.20180736910.1002/adfm.201807369 ↗
35. 10.1016/j.ijpharm.2020.11992810.1016/j.ijpharm.2020.119928 ↗
36. 10.1002/advs.20220327410.1002/advs.202203274 ↗
37. 10.1038/s41378-021-00302-w10.1038/s41378-021-00302-w ↗
38. 10.1038/s41551-021-00720-110.1038/s41551-021-00720-1 ↗
39. 10.1039/d2tb02040h10.1039/d2tb02040h ↗
40. 10.1021/acsnano.8b0537310.1021/acsnano.8b05373 ↗
41. 10.1002/advs.20220125410.1002/advs.202201254 ↗
42. 10.1002/smll.20210399710.1002/smll.202103997 ↗
43. 10.1016/j.biomaterials.2023.12202910.1016/j.biomaterials.2023.122029 ↗
44. 10.1038/nrd.2017.17010.1038/nrd.2017.170 ↗
45. 10.1021/acsami.2c2151610.1021/acsami.2c21516 ↗
46. 10.1080/15548627.2020.181634210.1080/15548627.2020.1816342 ↗
47. 10.1126/scitranslmed.abq506810.1126/scitranslmed.abq5068 ↗
48. 10.1007/s10456-023-09865-w10.1007/s10456-023-09865-w ↗
49. 10.1016/j.biopha.2022.11399610.1016/j.biopha.2022.113996 ↗